



Jul 08, 2022

Crystallization of ATG9 HDIR-ATG101:ATG13 complex

Adam Yokom¹¹University of California, Berkeley

1 Works for me

 Share

This protocol is published without a DOI.



Adam Yokom

DISCLAIMER

DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

ABSTRACT

Crystallization protocol for the ATG9 HDIR-ATG101:ATG13 complex

PROTOCOL CITATION

Adam Yokom 2022. Crystallization of ATG9 HDIR-ATG101:ATG13 complex.
protocols.io<https://protocols.io/view/crystallization-of-atg9-hdir-atg101-atg13-complex-cxmsxk6>

LICENSE

————— This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Jul 08, 2022

LAST MODIFIED

Jul 08, 2022

PROTOCOL INTEGER ID

66253

DISCLAIMER:

DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

Crystallization

- 1 ATG9 HDIR (828-839) fused ATG101 (1-198):ATG13 (1-197) complex was concentrated to 6 mg/ml in 25 mM HEPES pH 7.5, 150mM NaCl, 1mM MgCl₂, 1mM TCEP
- 2 Crystallization was carried out by sitting-drop vapor diffusion using an automated liquid-handling system (Mosquito, TTP LabTech, UK) at 288 K in 96-well plates
- 3 The protein solution was mixed with the reservoir buffer composed of 0.1 M HEPES pH 7.5, 0.2 M NaCl, 12% PEG8000 with a ratio of 1:1
- 4 Crystal trays were checked daily using a light microscopy for crystal growth
- 5 Large crystals were obtained in 2–4 days. Crystals were cryo-protected in 28% glycerol/reservoir buffer and frozen in liquid N₂